Published: Sun, August 13, 2017
Science | By Cecil Little

Editas Medicine, Inc. (EDIT) Stock Rating Reaffirmed by Cann


"(NASDAQ:EDIT) Rating Increased to Buy at Zacks Investment Research" was posted by BBNS and is the property of of BBNS. The lowest sales estimate is $1.30 million and the highest is $4.45 million. For the past 5 years, the company's revenue has grown 0%, while the company's earnings per share has grown 0%. Analysts anticipate that Editas Medicine will post ($3.04) EPS for the current fiscal year. Analysts might review their estimates as they will get closer to the actual results date. State Street added additional shares of Editas Medicine by 2.4% in the Q4.

The analysts wrote, "Editas' loss per share was $0.65, compared to our estimated loss of $1.01". Editas Medicine had a negative return on equity of 63.29% and a negative net margin of 1,864.00%. During the same period in the previous year, the firm earned ($0.54) earnings per share. The business's quarterly revenue was down 16.0% on a year-over-year basis.

EDIT has been the subject of a number of other reports. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 64 cents per share. Oppenheimer Holdings, Inc. reiterated a "market perform" rating on shares of Editas Medicine in a research note on Tuesday, July 18th. Cann started coverage on Editas Medicine in a report on Monday, July 17th. Finally, SunTrust Banks, Inc. began coverage on Editas Medicine in a research report on Thursday, July 13th. They issued a "hold" rating and a $17.00 target price for the company. Five research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. To sum up all these views, EDIT attains Median consensus rating in current rating pool. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and global copyright and trademark law.

North Korea tensions continue to weigh on global stocks
The remarks, following North Korea's earlier revelation of a plan to launch a salvo of ballistic missiles toward the U.S. Shares of Kohl's were down 8.4%, while Macy's fell 4% after the department store operators reported a fall in sales.


Frank's worldwide N.V. (NYSE:FI) has average revenue estimates of $120.3 Million, compared to low analyst estimates of $114.84 Million and high estimates of $122.4 Million for the current quarter. Director Boris Nikolic purchased 35,000 shares at an average price of $14.07 on Friday the 2nd. Following the transaction, the director now directly owns 35,000 shares in the company, valued at approximately $492,450. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

In related news, insider Gerald Frank Cox bought 4,000 shares of the company's stock in a transaction on Friday, June 2nd. The Stock becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume. The disclosure for this sale can be found here. The stock is a Buy among 0 brokerage firms polled by Factset Research. As of the end of the quarter Teachers Advisors, LLC had acquired 46,642 shares growing its position 316.7%. This gauge is crucial in determining whether investors are moved toward the direction of buying more of the stock, or else doing the contradictory side and selling more of the stock. Clough Capital Partners L P increased its stake in Editas Medicine by 678.0% in the first quarter. Driehaus Capital Management LLC now owns 125,684 shares of the company's stock worth $2,805,000 after buying an additional 79,104 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in shares of Editas Medicine during the second quarter valued at $127,000.

Frank's worldwide N.V. (NYSE:FI) shares traded on 1.28% up secure line and closed at $7.1. Creative Planning now owns 9,101 shares of the company's stock valued at $153,000 after buying an additional 9,000 shares during the last quarter.

Pearson into 100m hurdles final
World record holder Kendra Harrison took the early lead, but Pearson had the American covered by the second hurdle. Her next challenge will be winning a third successive Commonwealth title on home soil on the Gold Coast next year.


Presently Editas Medicine, Inc. Unusual volume can be a major signal that investment gurus and momentum traders are piling into a stock ahead of a catalyst. Editas Medicine has a 52 week low of $12.43 and a 52 week high of $29.20. The company's market cap is $698.10 million.

Shares of the company are trading at $19.72 which is significantly above $17.07, the 50 day moving average and which is slightly above the 200 day moving average of $18.99. The short interest to Editas Medicine Incorporated's float is 30.64%. The Company is involved in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment.

Stocks plunge over North Korea tensions
Shares of Kohl's were down 8.4%, while Macy's fell 4% after the department store operators reported a fall in sales. Hong Kong's Hang Seng Index plunged by 2 percent, while South Korea's Kospi Index slumped by 1.7 percent.


Like this: